Last updated: 2026-09-06 05:32:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cardiol Therapeutics Inc. (CRDL) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $2.20, with a market capitalisation of $253.51M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.88 to $2.28. This page covers its latest market performance, valuation, price trends and company information.
$253.51M | |
$2.16 | |
$4.96 | |
$0.45 | |
$2.16 | |
1.04M | |
-- | |
-- | |
$2.28 | |
$0.88 | |
-- | |
-- |
Cardiol Therapeutics Inc. (CRDL) last closed at $2.16 as of 2026-09-04 23:31:00, unchanged from the previous close of $2.16.
During the latest regular trading session, CRDL traded between $0.45 and $4.96, with a volume of 1.04M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Cardiol Therapeutics Inc. (CRDL) moved from $1.92 to $2.20, representing a gain of 14.32% ($0.27).
The stock traded between $2.13 and $2.22 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.52 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 94.3%
CRDL is currently trading at $2.20, placing it 94.3% of the way from its 52-week low of $0.88 to its 52-week high of $2.28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
| Employees | 18 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cardiol Therapeutics Inc. (CRDL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.